Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on July 27, 2004, to announce a key personnel change and to furnish its financial results for the fiscal quarter ended June 30, 2004. Dr. William Roberts has been appointed acting Vice President of Clinical Sciences, in addition to his current role as Vice President of Regulatory Development. This change follows the departure of Dr. Hans-Peter Guler. The company also provided its quarterly financial results via a press release, which is included as an exhibit to this filing. Investors should note that this report primarily serves to disclose these events and financial updates. While the press release details the financial performance for the quarter, the 8-K itself focuses on the procedural aspects of reporting these events and personnel changes. The information furnished is not considered 'filed' for SEC purposes unless specifically incorporated by reference into other filings.
Key Highlights
- 1Appointment of Dr. William Roberts as acting Vice President, Clinical Sciences.
- 2Dr. Roberts will hold this new role in addition to his existing position as Vice President, Regulatory Development.
- 3Resignation of Dr. Hans-Peter Guler, former Vice President, Clinical Sciences, effective July 23, 2004.
- 4The company furnished its financial results for the fiscal quarter ended June 30, 2004.
- 5A press release detailing the financial results is attached as Exhibit 99(a).
- 6The information provided in this 8-K is furnished under Regulation FD and Disclosure of Operations and Financial Condition, not deemed 'filed' unless specifically referenced elsewhere.